Results from the PRINCIPAL study to evaluate the real world effectiveness and safety of pazopanib in patients with advanced/metastatic renal cell carcinoma (RCC) were presented at the 2018 American Society for Clinical Oncology (ASCO) meeting in Chicago this week.
PRINCIPAL is the largest prospective real world study of pazopanib in patients with RCC. All patients aged 18 and above with advanced/metastatic clear cell RCC who began treatment with pazopanib within 30 days were eligible for this trial. Overall, 657 patients were enrolled, of which 507 (76.3%) completed the study. Two hundred and seventeen patients (33%) had more than 30 months of follow-up.
This observational study confirmed the effectiveness and safety of pazopanib in patients with advanced/metastatic RCC in a real world clinical setting.
